Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech CoSHSE:688073 +9.28%86 Days Payable is 101.37 as of Mar. 2026, which is 15% below its 10-year median of 119.65. GuruFocus rates SHSE:688073 with a GF Score™ of 86/100 and a GF Value™ of ¥67.40 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Bide Pharmatech Co ranks better than 59.44% on this metric.
The historical rank and industry rank for Bide Pharmatech Co's Days Payable or its related term are showing as below:
SHSE:688073'
s Days Payable Range Over the Past 10 Years
Min: 96.65 Med: 119.65 Max: 172.29
Current: 105.53
During the past 8 years, Bide Pharmatech Co's highest Days Payable was 172.29. The lowest was 96.65. And the median was 119.65.
SHSE:688073's Days Payable is ranked better than 59.44% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs SHSE:688073: 105.53
Bide Pharmatech Co's Days Payable
declined
from Mar. 2025 (123.67) to Mar. 2026 (101.37).
It may suggest that Bide Pharmatech Coaccelerated paying its suppliers.
The historical data trend for Bide Pharmatech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bide Pharmatech Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Bide Pharmatech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bide Pharmatech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co (SHSE:688073) has a Days Payable of 101.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bide Pharmatech Co and its competitors. This is 15% below median its historical median of 119.65. Over the past decade, Bide Pharmatech Co's Days Payable has ranged from 96.65 to 172.29. According to the industry distribution chart, Bide Pharmatech Co ranks #376 out of 927 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Bide Pharmatech Co's Days Payable too high?
Bide Pharmatech Co's current Days Payable of 101.37 is 15% below median its 10-year median of 119.65. Over the past 10 years, this metric has ranged from a low of 96.65 to a high of 172.29. The Drug Manufacturers industry median Days Payable is 90.28. Bide Pharmatech Co's value of 101.37 is 12.3% above this industry median. Based on the distribution chart, Bide Pharmatech Co ranks #376 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bide Pharmatech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bide Pharmatech Co ranks #376 out of 927 companies for Days Payable. This puts Bide Pharmatech Co in the upper half of its industry. The industry median Days Payable is 90.28. Bide Pharmatech Co's value of 101.37 is 12.3% above this benchmark. Historically, Bide Pharmatech Co's own Days Payable has ranged from 96.65 to 172.29 over the past decade. While the company's 10-year median is 119.65 vs. the industry median of 90.28, Bide Pharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bide Pharmatech Co's current Days Payable of 101.37 is 12.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bide Pharmatech Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bide Pharmatech Co's current Days Payable is 101.37, which is 15% below median its own 10-year median of 119.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥67.40, compared to a current price of ¥50.65 — trading 24.9% below its estimated fair value. The current Days Payable is 101.37, which is 15% below median its 10-year median of 119.65 and 12.3% above the Drug Manufacturers industry median of 90.28. Bide Pharmatech Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current Days Payable is 101.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥50.65 is trading 24.9% below its estimated GF Value™ of ¥67.40.
GuruFocus considers Bide Pharmatech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688073:
Days Payable: 101.37 (15% below median its 10-year median of 119.65)
GF Value™: ¥67.40 vs. price of ¥50.65 (24.9% below fair value)
Industry Position: 12.3% above the Drug Manufacturers median (#376 of 927)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
